News

Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug ...
PharmExec2h
Sanofi Advances Mid- to Late-Stage Respiratory Pipeline, Targeting Unmet Need in Asthma, COPD
New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...
Fierce Pharma2d
Sanofi, Regeneron score their 7th indication for Dupixent with FDA nod to treat hives condition
On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...
BioPharma Dive2d
Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent ...
BioSpace7d
FDA Action Alert: Regeneron, Sanofi and Abeona
Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...
Reuters12d
Sanofi SA
Sanofi to acquire Dren Bio's immunology unit ... 2.1 billion), which would be done between now and the end of December. Regeneron beats quarterly estimates on eczema drug demand; launches dividend ...
Regeneron Pharmaceuticals, Inc.: Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...
Reuters3d
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
April 18 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a ...